The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Molecular targeted therapy: Treating cancer with specificity
Abstract
ABSTRACT Molecular targeted therapies are revolutionized therapeutics which interfere with specific molecules to block cancer growth, progression, and metastasis. Many molecular targeted therapies approved by the Food and Drug Administration (FDA), have demonstrated remarkable clinical success in the treatment of a myriad of cancer types including breast, leukemia, colorectal, lung, and ovarian cancers. This review provides an update on the different types of molecular targeted therapies used in the treatment of cancer, focusing on the fundamentals of molecular targeted therapy, its mode of action in cancer treatment, as well as its advantages and limitations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Apoptosis and Molecular Targeting Therapy in Cancer
Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,121
RetractedContinuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
RNA-programmed genome editing in human cells
Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., & Doudna, J. (2013) · eLife · doi:10.7554/elife.00471 · Cited by 2,098
CRISPR–Cas9 Structures and Mechanisms
Jiang, F., & Doudna, J. A. (2017) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-062215-010822 · Cited by 2,029
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 815
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
Vu, T., & Claret, F. X. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00062 · Cited by 606
Trastuzumab emtansine: mechanisms of action and drug resistance
Barok, M., Joensuu, H., & Isola, J. (2014) · Breast Cancer Research · doi:10.1186/bcr3621 · Cited by 595
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 587
Targeting Bruton's tyrosine kinase in B cell malignancies
Hendriks, R. W., Yuvaraj, S., & Kil, L. P. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3702 · Cited by 552
Kim, G., Ison, G., McKee, A. E., Zhang, H., Tang, S., Gwise, T., Sridhara, R., Lee, E., Tzou, A., Philip, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0887 · Cited by 528
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Peters, C., & Brown, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150089 · Cited by 492
An overview of targeted cancer therapy
Padma, V. V. (2015) · BioMedicine · doi:10.7603/s40681-015-0019-4 · Cited by 459
Targeted therapies: a new generation of cancer treatments.
Gerber, D. E. (2008) · PubMed · Cited by 414
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Sampson, J. H., Aldape, K. D., Archer, G. E., Coan, A., Desjardins, A., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq157 · Cited by 370
Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Widakowich, C., de Castro, G., de Azambuja, E., Dinh, P., & Awada, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1443 · Cited by 324
Elucidating mechanisms of drug-induced toxicity
Liebler, D. C., & Guengerich, F. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1720 · Cited by 323
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Su, S., Hu, B., Shao, J., Shen, B., Du, J., Du, Y., Zhou, J., Yu, L., Zhang, L., Chen, F., et al. (2016) · Scientific Reports · doi:10.1038/srep20070 · Cited by 305
Mutant KRAS is a druggable target for pancreatic cancer
Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314307110 · Cited by 295
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
Guo, L., Zhang, H., & Chen, B. (2017) · Journal of Cancer · doi:10.7150/jca.17144 · Cited by 275
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 257
Tripathy, D., Bardia, A., & Sellers, W. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3157 · Cited by 247
Le Tourneau, C., Raymond, E., & Faivre, S. (2007) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2007.3.2.341 · Cited by 247
Gene therapy for cancer: present status and future perspective
Amer, M. H. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-27 · Cited by 244
Small RNA combination therapy for lung cancer
Xue, W., Dahlman, J. E., Tammela, T., Khan, O. F., Sood, S., Dave, A., Cai, W., Chirino, L. M., Yang, G. R., Bronson, R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412686111 · Cited by 242
KRAS mutation testing in metastatic colorectal cancer.
Tan, C., & Du, X. (2012) · PubMed · doi:10.3748/wjg.v18.i37.5171 · Cited by 227
van de Donk, N. W. C. J., Moreau, P., Plesner, T., Palumbo, A., Gay, F., Laubach, J. P., Malavasi, F., Avet-Loiseau, H., Mateos, M.-V., Sonneveld, P., et al. (2016) · Blood · doi:10.1182/blood-2015-10-646810 · Cited by 203
Small molecule activation of PKM2 in cancer cells induces serine auxotrophy
Kung, C., Hixon, J., Choe, S., Marks, K., Gross, S., Murphy, E., DeLaBarre, B., Cianchetta, G., Sethumadhavan, S., Wang, X., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.021 · Cited by 192
de Almagro, M. C., & Vucic, D. (2012) · PubMed · Cited by 191
De Palma, M., & Hanahan, D. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.011 · Cited by 183
Luque-Cabal, M., García-Teijido, P., Fernández-Pérez, Y., Sánchez-Lorenzo, L., & Palacio-Vázquez, I. (2016) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s34537 · Cited by 179
Collected Studies on Immunity.
(1906) · Journal of the American Medical Association · doi:10.1001/jama.1906.02520030066027 · Cited by 177
Balasubramaniam, S., Beaver, J. A., Horton, S., Fernandes, L. L., Tang, S., Horne, H. N., Liu, J., Liu, C., Schrieber, S. J., Yu, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1337 · Cited by 167
Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components
Dosio, F., Brusa, P., & Cattel, L. (2011) · Toxins · doi:10.3390/toxins3070848 · Cited by 166
Targeting MET in cancer therapy
Mo, H., & Liu, P. (2017) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.06.002 · Cited by 162
Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms
Liu, S., & Kurzrock, R. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.003 · Cited by 159
On-target and Off-target-based Toxicologic Effects
Rudmann, D. G. (2012) · Toxicologic Pathology · doi:10.1177/0192623312464311 · Cited by 156
Ehrlich, P., Bolduan, C. F., & Howard (1907) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-190708000-00032 · Cited by 152
Hideshima, T., Qi, J., Paranal, R. M., Tang, W., Greenberg, E. F., West, N. H., Colling, M. E., Estiu, G. L., Mazitschek, R., Perry, J. A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608067113 · Cited by 151
Tumor Microenvironment: A New Treatment Target for Cancer
Tsai, M., Chang, W., Huang, M., & Kuo, P. (2014) · ISRN Biochemistry · doi:10.1155/2014/351959 · Cited by 148
Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.
Glassman, P. M., & Balthasar, J. P. (2014) · PubMed Central · doi:10.7497/j.issn.2095-3941.2014.01.002 · Cited by 144
Targeted cancer therapy – Are the days of systemic chemotherapy numbered?
Joo, W. D., Visintin, I., & Mor, G. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.09.008 · Cited by 143
Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug
Rowe, J. M., & Löwenberg, B. (2013) · Blood · doi:10.1182/blood-2013-03-490482 · Cited by 143
Suzuki, M., Kato, C., & Kato, A. (2015) · Journal of Toxicologic Pathology · doi:10.1293/tox.2015-0031 · Cited by 141
Dienstmann, R., Braña, I., Rodon, J. A., & Tabernero, J. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0163 · Cited by 138
Small-molecule Bax agonists for cancer therapy
Xin, M., Li, R., Xie, M., Park, D., Owonikoko, T. K., Sica, G., Corsino, P. E., Zhou, J., Ding, C., White, M. A., et al. (2014) · Nature Communications · doi:10.1038/ncomms5935 · Cited by 133
Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene
Chen, Z., Yu, Y. P., Zuo, Z., Nelson, J. B., Michalopoulos, G. K., Monga, S. P., Liu, S., Tseng, G. C., & Luo, J. (2017) · Nature Biotechnology · doi:10.1038/nbt.3843 · Cited by 125
Zollo, M., Dato, V. D., Spano, D., Martino, D. D., Liguori, L., Marino, N., Vastolo, V., Navas, L., Garrone, B., Mangano, G., et al. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9473-5 · Cited by 111
Ras inhibition via direct Ras binding—is there a path forward?
Wang, W., Fang, G., & Rudolph, J. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.07.082 · Cited by 109
Evolution and Emergence of Therapeutic Monoclonal Antibodies
Foltz, I. N., Karow, M. L., & Wasserman, S. M. (2013) · Circulation · doi:10.1161/circulationaha.113.002033 · Cited by 109
Schlom, J., Hodge, J. W., Palena, C., Tsang, K.-Y., Jochéms, C., Greiner, J. W., Farsaci, B., Madan, R. A., Heery, C. R., & Gulley, J. L. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00002-0 · Cited by 103
Leung, E. L., Fan, X., Wong, M. P., Jiang, Z., Liu, Z., Yao, X., Lu, L., Zhou, Y., Yau, L.-F., Tin, V. P., et al. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6420 · Cited by 85
Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician
Lheureux, S., Denoyelle, C., Ohashi, P. S., Bono, J. S. D., & Mottaghy, F. M. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3695-3 · Cited by 74
Novel Points of Attack for Targeted Cancer Therapy
Røsland, G. V., & Engelsen, A. S. T. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12313 · Cited by 67
Armstrong, T. S., Wen, P. Y., Gilbert, M. R., & Schiff, D. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nor223 · Cited by 65
Monoclonal Antibodies as Magic Bullets
Brodsky, F. M. (1988) · Pharmaceutical Research · doi:10.1023/a:1015860525341 · Cited by 63
Azzariti, A., Porcelli, L., Simone, G. M., Quatrale, A. E., Colabufo, N. A., Berardi, F., Perrone, R., Zucchetti, M., D’Incalci, M., Xu, J., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1039-0 · Cited by 52
Wang, H., & Yan, C. (2011) · Neoplasia · doi:10.1593/neo.11438 · Cited by 50
Živný, J., Klener, P., Pytlík, R., & Anděra, L. (2009) · Current Pharmaceutical Design · doi:10.2174/138161210789941883 · Cited by 48
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer
Suda, K., & Mitsudomi, T. (2014) · Progress in tumor research · doi:10.1159/000355902 · Cited by 44
Capdeville, R., Silberman, S., & Dimitrijević, S. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80607-4 · Cited by 39
Abdollahpour‐Alitappeh, M., Karouei, S. M. H., Lotfinia, M., et al. (2018) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1449119 · Cited by 38
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
Vincenzi, B., Cremolini, C., Bianchi, A. S., Russo, A. D., Mannavola, F., Perrone, G., Pantano, F., Loupakis, F., Rossini, D., Ongaro, E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5231 · Cited by 37
Fourth World Antibody-Drug Conjugate Summit
Beck, A., Lambert, J. M., Sun, M. M. C., & Lin, K. (2012) · mAbs · doi:10.4161/mabs.21697 · Cited by 36
Target specificity and off-target effects as determinants of cancer drug efficacy
Shoshan, M. C., & Linder, S. T. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.3.273 · Cited by 35
Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics
Botham, R. C., Roth, H. S., Book, A. P., Roady, P. J., Fan, T. M., & Hergenrother, P. J. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00165 · Cited by 35
Advances in the proteomic discovery of novel therapeutic targets in cancer
Guo, S., Zou, J., & Wang, G. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s52216 · Cited by 34
Development of venetoclax for therapy of lymphoid malignancies
Zhu, H., & Almasan, A. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s109325 · Cited by 32
Bilušić, M., & Madan, R. A. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3182068cdb · Cited by 31
World Antibody Drug Conjugate Summit Europe
Beck, A., Senter, P. D., & Chari, R. V. J. (2011) · mAbs · doi:10.4161/mabs.3.4.16612 · Cited by 31
Targeted therapy: resistance and re-sensitization
Chen, D., & Zhang, X.-S. (2015) · 癌症:英文版 · doi:10.1186/s40880-015-0047-1 · Cited by 31
Niraparib for the treatment of ovarian cancer
Kanjanapan, Y., Lheureux, S., & Oza, A. M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1297423 · Cited by 30
Progress in Cancer Chemotherapy with Special Stress on Molecular-targeted Therapy
Saijo, N. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq035 · Cited by 28
Commentary: Tackling the Challenges of Developing Targeted Therapies for Cancer
Schilsky, R. L., Allen, J. D., Benner, J. S., Sigal, E. V., & McClellan, M. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0079 · Cited by 22
Jacobs, S. A. (2007) · PubMed Central · Cited by 20
Molecularly Targeted Therapy: Past, Present and Future
Kimura, A. (2012) · Chemotherapy Open access · doi:10.4172/2167-7700.1000105 · Cited by 15
Alemtuzumab for multiple sclerosis: the new concept of immunomodulation
Gallo, P., Centonze, D., & Marrosu, M. G. (2017) · Multiple Sclerosis and Demyelinating Disorders · doi:10.1186/s40893-017-0024-4 · Cited by 15
Characteristics of rare diseases
Tankovic, G. (2013) · Elsevier eBooks · doi:10.1533/9781908818393.55 · Cited by 2
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Metadata
- Authors
- Lee, Y. T., Tan, Y. J., & Oon, C. E.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 834
- Pages
- 188-196
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2884126108
- Cited by
- 1,067
- References
- 89
- FWCI
- 43.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.